Is PFE stock overvalued right now?

PFE is trading near our fair value estimate of $24.15, within a normal valuation band.

What is PFE fair value based on current fundamentals?

Our fair value estimate for PFE is $24.15, derived from discounted cash flow, dividend discount, and relative valuation multiples. The estimate assumes a discount rate of 9.0% and terminal growth of 2.5%.

How risky is PFE compared with other stocks?

PFE carries a beta of 0.30 suggests a defensive profile. Investors should weigh macro exposure against their own risk tolerance.

Is PFE still growing?

Latest trailing metrics show revenue growth of 2.6%. Profit margins are 6.8%.

What do analysts think about PFE?

Analyst consensus target is $28.88, implying 5.6% upside. The street recommendation is "buy".

Does PFE pay a dividend?

Yes. PFE currently offers a dividend yield of 6.2%.

What could change the investment case for PFE?

Key catalysts include Healthcare sector dynamics, interest rate shifts, and company-specific earnings surprises. Monitor macro risk scores and analyst estimate revisions for early signals.

HealthcareUpdated·Data: Yahoo Finance, SEC EDGAR·Data delayed ~5 min

Analysis PFE 100% YoY Growth Patent Pipeline result Battery

NYQ · Healthcare · Drug Manufacturers - General

$27.35

-0.37 (-1.33%)

Stock valuation guide Macro risk explained guide

About the Author

Phasakorn Traklang (Peach) — Founder

Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.

Connect on LinkedIn

Investment Disclaimer: QuantSoar is for informational purposes only. We do not provide personalized investment advice. Always conduct your own research or consult a financial advisor. SEC

Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.